Trial Profile
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms NILE
- Sponsors AstraZeneca; AstraZeneca AB
- 09 Feb 2024 Planned End Date changed from 30 Oct 2025 to 30 Jun 2025.
- 09 Feb 2024 Planned primary completion date changed from 15 Jan 2024 to 30 Aug 2024.
- 09 Feb 2024 Status changed from recruiting to active, no longer recruiting.